Bahija Jallal is the founder of Immunocore. Immunocore has raised $665M in total funding. Latest round: Series C. Based in Abingdon, United Kingdom.
Bahija Jallal is the CEO of Immunocore, a commercial-stage biotechnology company based in Abingdon, United Kingdom. Immunocore focuses on developing T cell receptor-based immunotherapies for cancer, infectious diseases, and autoimmune conditions. The company utilizes its proprietary ImmTAC molecules, notably developing KIMMTRAK, the first bispecific T cell receptor therapy approved for solid tumors. Immunocore has raised a total of $664.8 million across four funding rounds, including a $320 million private financing round in 2015 and $40 million from the Bill & Melinda Gates Foundation in 2017. Jallal's background is as a researcher turned CEO.
Full founder directory · Investor directory · Company funding database · Fundraising library